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Abstract
Background: The bone morphogenetic proteins (BMPs) belong to a unique group of proteins that includes the
growth factor TGF-b. BMPs play important roles in cell differentiation, cell proliferation, and inhibition of cell
growth. They also participate in the maturation of several cell types, depending on the microenvironment and
interactions with other regulatory factors. Depending on their concentration gradient, the BMPs can attract various
types of cells and act as chemotactic, mitogenic, or differentiation agents. BMPs can interfere with cell proliferation
and the formation of cartilage and bone. In addition, BMPs can induce the differentiation of mesenchymal
progenitor cells into various cell types, including chondroblasts and osteoblasts. The aim of this study was to
analyze the effects of treatment with rhBMP-2 on the proliferation of canine mesenchymal stem cells (cMSCs) and
the tumor suppression properties of rhBMP-2 in canine osteocarcoma (OST) cells. Osteosarcoma cell lines were
isolated from biopsies and excisions of animals with osteosarcoma and were characterized by the Laboratory of
Biochemistry and Biophysics, Butantan Institute. The mesenchymal stem cells were derived from the bone marrow
of canine fetuses (cMSCs) and belong to the University of São Paulo, College of Veterinary Medicine (FMVZ-USP)
stem cell bank. After expansion, the cells were cultured in a 12-well Transwell system; cells were treated with bone
marrow mesenchymal stem cells associated with rhBMP2. Expression of the intracytoplasmic and nuclear markers
such as Caspase-3, Bax, Bad, Bcl-2, Ki-67, p53, Oct3/4, Nanog, Stro-1 were performed by flow citometry.
Results: We evaluated the regenerative potential of in vitro treatment with rhBMP-2 and found that both
osteogenic induction and tumor regression occur in stem cells from canine bone marrow. rhBMP-2 inhibits the
proliferation capacity of OST cells by mechanisms of apoptosis and tumor suppression mediated by p53.
Conclusion: We propose that rhBMP-2 has great therapeutic potential in bone marrow cells by serving as a tumor
suppressor to increase p53 and the pro-apoptotic proteins Bad and Bax, as well as by increasing the activity of
phosphorylated caspase 3.
Study design: Canine bone marrow mesenchymal stem cells associated with rhBMP2 in canine osteosarcoma
treatment: “in vitro“ study
Keywords: Osteosarcoma, rhBMP-2, Mesenchymal stem cell, Canine
Background
Osteosarcoma is as a primary bone cancer common in
dogs. Frequently, osteosarcoma affects the limb bones of
large-sized dogs over 15 kg at an average age of 7 years
[1]. In 75% of cases, osteosarcoma affects either the
appendicular skeleton [2] or the pelvic and thoracic
limbs, and in the remaining 25%, it affects the axial ske-
leton or the flat bones [3,4]. Generally, males have a
higher incidence of osteocarcoma than females [2], with
the exception of the St. Bernard, Rottweiler, and Danish
breeds, in which females are most affected [5,6]. Osteo-
sarcoma cells induce platelet aggregation, which facili-
tates metastasis formation. Platelet aggregation and
metastasis most commonly occur in the lung [7]. Plate-
let aggregation promotes the establishment of tumor
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the tumor cells and the vascular surfaces [6].
A primary extraskeletal osteosarcoma has a metastatic
rate that ranges from 60 to 85% in dogs and an average
life expectancy after surgery of 26-90 days, which varies
according to the location where the metastasis occurs
[4].
Metastasis is the most common cause of death in dogs
with osteosarcoma, and 90% of dogs either die or are
euthanized due to complications associated with lung
metastases. Therefore, chemotherapy is used to increase
the long-term survival of dogs with osteosarcoma. To
reduce the occurrence of metastasis, chemotherapy is
often used in combination with surgery or radiotherapy.
Specifically, either cisplatin or cisplatin and doxorubicin
are chemotherapeutic agents used in dogs [8,9]. Numer-
ous studies have aimed to develop antiangiogenic thera-
peutic strategies, which can be combined with other
treatments [10].
The bone morphogenetic proteins (BMPs) belong to
a unique group of proteins that includes the growth
factor TGF-b. BMPs play important roles in cell differ-
entiation, cell proliferation, and inhibition of cell
growth. They also participate in the maturation of sev-
eral cell types, depending on the microenvironment
and interactions with other regulatory factors [11,12].
Depending on their concentration gradient, the BMPs
can attract various types of cells [13] and act as che-
motactic, mitogenic, or differentiation agents [14].
BMPs can interfere with the proliferation of cells and
the formation of cartilage and bone. Finally, BMPs can
also induce the differentiation of mesenchymal pro-
genitor cells into various cell types, including chondro-
blasts and osteoblasts [15].
BMPs play important roles in cell differentiation, pro-
liferation, morphogenesis, and apoptosis, and recent stu-
dies have shown that recombinant human BMP-2
(rhBMP-2) inhibits tumor formation [16-19]. However,
t h er o l eo fr h B M P - 2i nc a n i ne osteosarcoma remains
u n k n o w n .T h eo s t e o i n d u c t i v ec a p a c i t yo fr h B M P - 2h a s
been widely studied in preclinical models and evaluated
in the clinical setting [20]. Gene and cell therapy studies
have shown that many bone defects can be treated by
implantation of resorbable polymers with bone marrow
cells transduced with an adenovirus expressing rhBMP-2
[21]. In addition, rhBMP-2 can be used as a substitute
for bone grafts in spinal surgery, with results compar-
able to autogenous grafts [22].
Based on the studies cited above, the present work
explores the proliferative effects of canine mesenchymal
stem cells (cMSCs) and osteosarcoma (OST) cells trea-
ted with rhBMP-2 to evaluate their regenerative poten-
tial in the presence of the in vitro treatment.
Methods
Isolation of canine osteosarcoma (OST) cells
The osteosarcoma cell lines were isolated from biopsies
and excisions of animals with osteosarcoma performed
in veterinary clinics and hospitals in São Paulo and were
characterized by the Laboratory of Biochemistry and
Biophysics, Butantan Institute. Approved by Ethic Com-
mittee in the use of animals, protocol number 1654/
2009. After harvesting the tissue, the fragments were
washed with saline solution containing antibiotics (10%),
and the fatty and hemorrhagic tissues were removed
from the tumors. Next, the tumors were divided in two
samples. The first sample was cut into pieces of 0.01
cm
2 using a scalpel and adhered to Petri dishes for 1 h
in fetal bovine serum (FBS) in an incubator at 37°C and
5% CO2. The second sample was used for histopatholo-
gical diagnosis. The cells were cultured in 25-cm
2 flasks
with DMEM-H (LGC) media supplemented with 10% of
FBS (VITROCELL), 1% of penicillin and streptomycin
(GIBCO), and 1% of pyruvic acid (GIBCO) at pH 7.4
and were kept in a incubator at 37°C and 5% CO2.T h e
cells grew in a monolayer attached to the surface of the
culture plate. The sub-culture of cells was performed by
trypsinizaton of the confluent monolayer cell cultures
every 3 days.
Isolation of mesenchymal stem cells derived from canines
fetuses (cMSCs)
The mesenchymal stem cells were derived from the
bone marrow of canine fetuses (cMSCs) and belong to
the University of São Paulo, College of Veterinary Medi-
cine (FMVZ-USP) stem cell bank. Approved by Ethic
Committee in the use of animals, protocol number 931/
2006. cMSCs were cultured in 25 cm
2 flasks with
ALPHA-MEM media (VITROCELL) supplemented with
10% of HyClone FBS, 1% of penicillin and streptomycin
(GIBCO), 1% of nonessential amino acids (GIBCO), and
1% L-glutamine (GIBCO) at pH 7.4, and they were kept
in an incubator at 37°C and 5% CO2. The cells grew in
a monolayer attached to the surface of the culture plate.
The sub-culture of cells was performed from the mono-
layer cells.
In vitro treatment of osteosarcoma with stem cells
derived from canine bone marrow and rhBMP-2
After expansion, the OST and cMSCs cells were cul-
tured in a 12-well plates containing 10
5 cells per well.
The groups was composed by OST cells untreated (con-
trol group 1) and cMSCs untreated (control group 2).
These cells were treated with different concentrations
of rhBMP-2 (5, 10, and 20 nM) for 120 h. Cells were
labeled with carboxyfluorescein diacetate succinimidyl
diester (CFSE; Invitrogen, Carlsbad, CA, USA) by
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CFSE at a density of 2 × 10
6 cells/ml in PBS and the
reaction was stopped by adding bovine serum to the
PBS. At different times of culture, the cells were har-
vested and directly run on the FACSCalibur flow cyt-
ometer (Becton Dickinson) to measure the intensity of
CFSE in the cells in order to monitor the number of
times that the cells had divided during culture.
Then a total of 3 × 10
5 cells were cultured in 96 U-bot-
tom well plates and were kept in an incubator at 37°C and
5% CO2 for 5 days. After the incubation period, the prolif-
eration of the OST cells and the cMSCs was measured to
standardize the optimal concentration to be used in the in
vitro regenerative therapy of canine osteosarcoma.
For transwell culture the cMSCs treated with rhBMP2
(20 nM) were cultured onto dry 6.5 mm diameter, 0.4
μm pore size polycarbonate Transwell filters containing
10
5 cells per filter. OST cells treated with rhBMP2 (5
nM) was added to the lower well, containing 10
5 cells
per well. This treatment lasted for 120 h.
Expression of cell proliferation and cell death markers
The cells obtained from the Transwell culture plates were
trypsinized and inactivated with FBS, centrifuged at 1,500
rpm for 10 min, and the supernatant was discarded. The
pellet was resuspended in 5 ml of PBS at a concentration
of 10
6 cells/ml. To analyze the amounts of intracytoplas-
mic and nuclear markers, the cells were permeabilized
with 5 μl of 0.1% Triton X-100 for 30 min before the addi-
tion of specific primary antibodies. The following markers
were used to determine the cell death pathways: caspase-3,
Bax, Bad, and Bcl-2. The antibodies for Ki-67 and p53
were used to determine the proliferation index. Mesenchy-
mal stem cell differentiation and maturation was deter-
mined by using the Oct 3/4, Stro-1, and Nanog antibodies.
The samples were analyzed in a flow cytometer (FACSCa-
libur), and the expression of the markers was determined
by comparison with an isotype control.
Statistical analysis
All the values reported are mean ± SD. Statistical ana-
lyses were performed using GraphPad Prism Version 5
software and significance was determined using either
the nonparametric MannWhitney test for unpaired data
or the two-tailed t-test. Difference was considered signif-
icant at p < 0.05. In all graphs, *, **, *** indicate differ-
ence between groups at p < 0.05, 0.01 and 0.001,
respectively.
Results
Proliferative effects of rhBMP-2 in canine mesenchymal
stem cells (cMSCs) and canine osteosarcoma (OST) cells
cMSCs cells showed an enhanced cellular proliferation
response in comparison to OST cells when treated with
20 nM of rhBMP-2 for 120 h. A significant proliferative
response was observed in OST after treatment with 5
nM of rhBMP-2 (Figure 1).
Expression of cellular markers in canine osteosarcoma
cells treated with cMSCs and rhBMP-2
Oct 3/4 and Nanog are markers of pluripotent
embryonic stem cells. We analyzed the expression of
these markers in cMSCs treated with rhBMP-2 (20
nM) decreased the expression of Oct 3/4 and Nanog
in the bone marrow cells. Stro-1 and CD90 are surface
markers of mesenchymal stem cells that specifically
possess osteogenic potential. We observed an increase
in the Stro-1 marker when the osteosarcoma cells were
treated with rhBMP-2 (5 nM). This increase correlates
with the finding that rhBMP-2 is expressed in some
types of osteosarcoma, as observed in the OST cells
(Figure 2A). A significant reduction in the expression
of the pluripotent embryonic stem cell markers (Oct
3/4 and Nanog) and the mesenchymal stem cells mar-
kers (CD90 and Stro-1) was observed in the canine
bone marrow cells treated with rhBMP-2, as shown in
Figure 2B.
Flow cytometric analyses of markers of proliferation and
cell death by apoptosis or necrosis
The treatment of cMSCs with rhBMP-2 induced an
increase in proliferation followed by a significant
increase in the expression of the Ki-67 marker. We
observed a decrease in the expression of p53, which is
involved in the regulation of apoptosis and tumor sup-
pression. Treatment with rhBMP-2 can activate p53
when DNA damage is present, and this occurs without
the involvement of cMSCs in the tumorigenic processes
or an increase in apoptosis via phosphorylated caspase-
3. We also observed a significant increase in the expres-
sion of the anti-apoptotic protein Bcl-2 and a decrease
in phosphorylated caspase-3 after treatment with
rhBMP-2. There was a inhibition of cell proliferation in
the OST cells treated with rhBMP-2, which promotes a
significant increase in p53 expression. An increased
induction of cell death mediated by pro-apoptotic pro-
teins (Bax) was observed, resulting in suppression of
proliferation and an increase of phosphorylated caspase-
3 (Figure 3).
The treatment of osteosarcoma with cMSCs treated
with rhBMP-2 induced a significant decrease in the
expression of the P53 marker which is involved in the
regulation of apoptosis and tumor suppression. We
observed a decrease in the expression of Ki67, which is
involved in the cellular proliferation. The treatment had
shown a significant increase in apoptosis via phosphory-
lated caspase-3 and in the expression of the pro-apopto-
tic protein Bax and a significant decrease in the
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and 5).
Discussion
In the present study, we analyzed the effects of rhBMP-
2 in mesenchymal stem cells for use in the regenerative
therapy of canine osteosarcoma utilizing OST cells as a
model. The OST cells remained spindle-shaped during
cell growth and the confluent stages.
Treatment of OST cells with rhBMP-2 compromised
the osteoblastic phenotype. Osteoprogenitors are either
pre-determined or inducible, depending on additional
signals necessary to cause differentiation. This difference
is important because it reflects the variation between
cell compromise, which is when cell fate is programmed,
and cell differentiation, which is when cells are compro-
mised by permissive microenvironment signs [23].
Although the exact function and interrelation of each
type of BMP are not completely understood, evidence
indicates that they are a part of a series of complex fac-
tors that regulate cell differentiation, specifically matura-
tion intochondroblasts and osteoblasts. The structural
and functional evolutionary conservation of genes
encoding BMPs suggest that these genes have critical
regulatory functions in the process of differentiation
during development and neoplastic transformation. In
human colorectal carcinoma, for example, rhBMP-2 acts
as a tumor suppressor [24]. Similarly, rhBMP-2 shows
anti-proliferative and pro-apoptotic potential in gastric,
prostate, and ovarian cancer cells. In breast cancer cell
lines, rhBMP-2 treatment decreases cell proliferation.
The effects of the BMPs varies with tumor progression.
In other words, in the early stages of carcinogenesis, the
TGF beta superfamily acts by suppressing tumor growth,
and at later stages, the superfamily actually promotes
tumor progression [25].
In our findings, we observed that when mesenchymal
stem cells were exposed to rhBMP-2, there was a signifi-
cant reduction in the expression of the marker Nanog.
We noted a significant decrease in expression of the cell
proliferation marker Oct 3/4 in OST cells treated with
rhBMP-2. The treatment of OST cells with rhBMP-2
after Transwell culture inhibited the proliferative
response (Ki-67 expression) and promoted an increase
in cell death mediated by the pro-apoptotic proteins
(Bax and Bad), resulting in suppression of proliferation
and an increase of phosphorylation of caspase-3.
The treatment of bone marrow cells with rhBMP-2
stimulates the production of growth and differentiation
factors. Thus, rhBMP-2 treatment may be a relevant
treatment for canine osteosarcoma cells. Eliseev et al.
[26], showed that rhBMP-2 increases the expression of
Bax via Runx2, thus increasing the sensitivity of osteo-
sarcoma cells to apoptosis. In our experiments, we also
observed an increase in Bax expression when canine
osteosarcoma cells were treated with rhBMP-2. These
results suggest that rhBMP-2 treatment increases the
susceptibility of OST cells to death by apoptosis.
Figure 1 Proliferation curves. Proliferation curves of bone marrow stem cells derived from canine fetuses (cMSCs) and canine osteosarcoma
(OST) cells 120 h after rhBMP-2 treatment. The cells were stained with CSFE and analyzed by flow cytometry. Statistical differences were
obtained by analysis of variance (*** p < 0.001, ** p < 0.01, * p < 0.05).
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the growth of human multiple myeloma U266 cells by
arresting the cells in the G1 phase of the cell cycle,
leading to apoptosis. The combined treatment with
rhBMP-2 induces cell cycle inhibitory proteins, such as
p21 and p27, and induces other proteins associated
with apoptosis, such as Bcl-xl, Bcl2, Bax, and Bad.
Thus, rhBMP-2 may be an important tool for the
treatment of multiple myeloma due to its anti-tumor
and bone regeneration effects. Kawamura et al. [17]
investigated the antiproliferative effect of rhBMP-2 in
myeloma cells and found that BMPs inactivate the
STAT3 protein, which is a signal transducer activated
by IL-6. BMPs were also found to increase the expres-
sion of cell cycle inhibitors leading to a cell replication
blockage via pRb.
Figure 2 Pluripotent embryonic stem cell markers. Expression of pluripotent embryonic stem cell markers (Nanog and Oct 3/4) and markers
of mesenchymal stem cells with osteogenic potential (Stro-1 and CD90) in OST cells (A) and cMSCs (B) from the control and the group treated
with rhBMP-2 (5 nM e 20 nM respectively) for 120 h. Statistical differences were obtained by analysis of variance (*** p < 0.001, ** p < 0.01).
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function either as an oncogene or as a tumor suppres-
sor, depending on the stage of disease. The effects of
BMPs are cell type-specific and may vary among differ-
ent tumors. BMPs are also reported as tumor suppres-
sors and act on the cell cycle by inducing apoptosis of
abnormal cells, such as tumors. Hardwick et al. [24]
used cell lines of colorectal cancer to evaluate the role
o fr h B M P - 2 .T h e yo b s e r v e dt h a tr h B M P - 2r e d u c e dc e l l
growth and stimulated apoptosis due to high levels of
phosphorylated caspase-3. In our results, we also
observed a decrease in cell growth when OST cells were
treated with rhBMP-2, and we observed an increase of
caspase-3 levels.
Treatment with rhBMP-2 may be a new therapeutic
option for canine osteosarcoma. We found that rhBMP-
2 decreases the expression of embryonic stem cell mar-
kers Nanog and Oct 3/4 in different treatment regimens,
and it is also associated with tumorigenesis of many
types of cancer [28,29]. Because rhBMP-2 has the poten-
tial to inhibit the expression of markers such as Nanog
and Oct 3/4, it may also exhibit anti-tumor effects in
animal models in vivo. Oct 3/4 and Nanog are impor-
tant factors in the regulation of self-renewal and the
pluripotency of embryonic stem cells. There are studies
showing a correlation of these cells with cases of tumor-
igenesis [29]. Oct 3/4 is a marker for both adult stem
cells and cancer stem cells. Inhibition of this factor can
Figure 3 Pro and anti-apoptotic proteins and the proliferative capacity. Expression of pro- and anti-apoptotic proteins and the proliferative
capacity in cMSCs (A) and OST cells (B) 120 h after treatment with rhBMP-2 (20 nM and 5 nM respectively) analyzed by flow cytometry.
Statistical differences were obtained by analysis of variance (*** p < 0.001, ** p < 0.01).
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tumorigenesis.
Osteogenesis is defined by a series of events, which starts
with a commitment to an osteogenic lineage by mesenchy-
mal cells. Subsequently, these cells proliferate and demon-
strate an upregulation of osteoblast-specific genes and
mineralization. Multiple signaling pathways have been
demonstrated to participate in the differentiation of an
osteoblast progenitor to a committed osteoblast [30,31].
An association between the expression of STRO-1 and
the presence of cells with osteogenic potential has been
demonstrated in precursor adult human bone marrow.
STRO-1
+ population of human bone marrow cells is
capable of osteogenic differentiation. The expression
STRO-1 is complicated by the fact that a considerable
proportion of STRO-1
+ cells are not of the osteogenic
lineage and the exact stage of osteogenic differentiation
at which STRO-1 is expressed remains unclear, espe-
cially when working with cultured cell populations and
the coexpression of STRO-1 and a panel of antibodies
recognizing cell surface determinants which may be
regulated during osteogenic differentiation [32].
BMP-2 alone does not induce osteogenesis in isolates
of human bone marrow stromal cells as measured by
Figure 4 Pro apoptotic effects of osteosarcoma treatment with cMSCs associated with rhBMP2. Markers expression of osteosarcoma
treatment with cMSCs and cMSCs treated with rhBMP2 (5 nM) for 120 after treatment analyzed by flow cytometry. Statistical differences were
obtained by analysis of variance (*** p < 0.001, ** p < 0.01).
Figure 5 Comparison between different treatments. Markers expression of osteosarcoma treatment with cMSCs, rhBMP2 and cMSCs treated
with rhBMP2 (5 nM) 120 h after treatment analyzed by flow cytometry. Statistical differences were obtained by analysis of variance (*** p <
0.001, ** p < 0.01).
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ever, BMP-2 does induce other markers associated with
differentiation of osteoblasts. This osteogenic capacity is
seen in stromal cells isolated from mice, rats, rabbits,
and humans; however, cell behavior and efficacy of
inducers varies in a species-dependent manner [33].
BMP-2 stimulates surrounding tissues; however, more
robust data is needed to demonstrate that BMP-2 also
augments the osteogenic potential of implanted MSCs
cells. In the present study, probably the effects of MSCs
and rBMP-2 treated model culture Transwell, controlled
environmental niches and alterations in this microenvir-
onment can dramatically modify their behavior and dif-
ferentiation capacities.
Langenfeld et al. [34] showed that cell culture condi-
tions and the intra- and extra-cellular antagonist con-
centrations interfere with the biological activities of
BMPs. Wang et al. [23] observed that rhBMP-2 inhibits
the tumorigenic potential of human osteosarcoma
OS99-1 cells. The inhibition was due to a decrease in
the expression of proteins associated with tumorigenesis
and an increase of osteosarcoma cell differentiation in
response to rhBMP-2. Thus, rhBMP-2 could be consid-
ered a novel tool for the treatment of human osteosar-
coma. Our study clearly showed that the association of
mesenchymal stem cells derived from canine fetal bone
marrow, combined with rhBMP-2, decreases the tumori-
genic potential of canine osteosarcoma cells in vitro.
Conclusions
The in vitro treatment of bone marrow cells with
rhBMP-2 decreased their osteogenic potential. Thus, we
suggest that the treatment conditions for both osteo-
genic induction and for tumor regression are favorable
when associated with stem cells derived from canine
bone marrow. cMSCs treated with rhBMP-2 inhibits the
proliferation capacity of OST cells by mechanisms of
apoptosis and tumor suppression mediated by p53.
Treatment of bone marrow cells with rhBMP-2 showed
a high therapeutic potential observed by the increase in
the tumor suppressor protein p53 and pro-apoptotic
proteins Bad and Bax, and by increased activity of phos-
phorylated caspase-3.
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